Features | Partner Sites | Information | LinkXpress
Sign In
AB Sciex
RANDOX LABORATORIES
FOCUS DIAGNOSTICS, INC.

Inflammatory Biomarkers Predict Chronic Pulmonary Disease Outcome

By Labmedica International staff writers
Posted on 03 Apr 2012
Changes in inflammatory biomarkers establish clinical variables and improve the prediction of mortality in patients with chronic obstructive pulmonary disease (COPD).

COPD is characterized by low-grade systemic inflammation and the addition of inflammatory biomarker blood tests would establish predictive factors that will improve accuracy of a prognostic model for mortality.

An international multicenter team of scientists led by those at Brigham and Women’s Hospital (Boston, MA, USA) prospectively collected data on 1,843 COPD patients from the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) study. Of these 1,843 patients, 168 (9.1%) died during the three-year follow-up.

The biomarkers measured from serum samples were: Chemokine (C-C motif) ligand 18 (CCL-18 or pulmonary and activation-regulated chemokine, PARC), surfactant protein D (SP-D), interleukin 8 (IL-8), Clara cell secretory protein 16 (CC-16), and tumor necrosis factor alpha (TNFα). Fibrinogen and C-reactive protein (CRP using a high sensitivity method) were measured in plasma samples. All protein biomarkers were measured by validated immunoassays. Total white blood cells (WBC) and neutrophils were counted by an automated method.

The results of the study show that a panel of selected biomarkers, WBC counts, IL-6, fibrinogen, CCL-18, CRP, IL-8, and SP-D were not only elevated in nonsurvivors compared with survivors, but were also associated with mortality over three years after adjusting for clinical variables known to predict death in COPD. Bartolome M. Celli, MD, the lead author of the study, said, "Adding white blood cell counts and measurement of changes in systemic levels of IL-6, CRP, IL-8, fibrinogen, CCL-18, and SP-D significantly improves the ability of clinical variables to predict mortality in patients with COPD. This is the first study to show that the addition of biomarker levels to clinical predictors in COPD patients adds relevant prognostic information." The study was published on March 23, 2012, in the American Journal of Respiratory and Critical Care Medicine.

Related Links:
Brigham and Women’s Hospital



DRG International
77 ELEKTRONIKA
DiagCor Bioscience
comments powered by Disqus
Life Technologies

Channels

Industry News

view channel

GlaxoSmithKline Boosts Global Cancer Testing With GE Healthcare Deal

The new agreement between GE Healthcare-subsidiary Clarient (Aliso Viejo, CA, USA) and GlaxoSmithKline (GSK; Brentford, UK) will create a force in cancer testing, according to Kalorama Information (New York City, NY, USA). The two entities will form a multipurpose, data analytics- and companion diagnostics (CDx)-driven... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.